-
Mashup Score: 5NIH funds research for three experimental ALS drugs - 12 day(s) ago
The funding, which is part of ACT for ALS, will support expanded access studies of drugs developed by Prilenia Therapeutics, Clene Nanomedicine and Rapa Therapeutics.
Source: www.biopharmadive.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 3Pharmas form joint venture to jumpstart Japanese drug research - 18 day(s) ago
A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.
Source: www.biopharmadive.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 1Vertex to buy kidney disease drugmaker Alpine for $4.9B - 29 day(s) ago
The deal, which company CEO Reshma Kewalramani described “just the right fit,” is the largest acquistion in Vertex’s 35-year history.
Source: www.biopharmadive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Denali Therapeutics to receive $500M in private financing - 2 month(s) ago
After news of a trial failure for a closely-watched ALS drug and a company restructure, Denali announced plans to extend its cash runway into 2028.
Source: www.biopharmadive.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 8
Newly named partner Anthony Philippakis and managing partner Krishna Yeshwant spoke with BioPharma Dive about biotech’s newfound optimism and their investing “North Star.”
Source: www.biopharmadive.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0J&J to acquire ADC drug developer Ambrx for $2B - 4 month(s) ago
The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.
Source: www.biopharmadive.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 1Biotech M&A is picking back up. Here are the latest deals. - 4 month(s) ago
December dealmaking by Bristol Myers, AbbVie, Roche and AstraZeneca helped push the total value of biotech M&A in 2023 to the highest level in four years.
Source: www.biopharmadive.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 210 clinical trials to watch in the first half of 2024 - 4 month(s) ago
A non-addictive pain pill faces its definitive test, while study results in ALS, a rare heart disease and lung cancer could have far-reaching implications.
Source: www.biopharmadive.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 0Bristol Myers to acquire brain drug developer Karuna for $14B - 4 month(s) ago
The deal would hand Bristol Myers, which is reprioritizing neuroscience research, an experimental treatment for schizophrenia that analysts think could become a blockbuster product.
Source: www.biopharmadive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1
The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.
Source: www.biopharmadive.comCategories: General Medicine News, General HCPsTweet
RT @BrielmaierL: NIH funds research for three experimental ALS drugs https://t.co/2SleK9a7uV via @BioPharmaDive